AzTrials
AzTrials

Bronchiolitis AcutePICUFUNNCT03345628

Feasibility Study for Neurodevelopment Follow-up Study in PICU

An observational study of Bronchiolitis Acute and Pneumonia, run by McGill University Health Centre/Research Institute of the McGill University Health Centre at 1 site in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

There is a large and growing body of animal evidence demonstrating neuroapoptosis and neurodevelopmental abnormalities after exposure to anesthetic agents. This has prompted an FDA warning concerning use of anesthetics and sedatives in children under 3 years of age. Read more about this study

Who is it for?
Ages Up to 52 weeks
Conditions the study is for
Bronchiolitis Acute, Pneumonia
What is being tested?
Sedatives
How many people
40 participants
Where
1 siteCanada
Study dates
1 Feb 2018to 30 Dec 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 52 weeks
  • All sexes
  • No healthy volunteers
  • Child

Study population: PICU admissions for respiratory disease as specified in eligibility section recruited at 6 years of age

Who may be able to join

  • infants treated for bronchiolitis or pneumonia requiring respiratory support either intubation and IPPV needing sedation OR requiring non-invasive ventilation without sedation

Who cannot join

  • prematurity less than 28 weeks, congenital heart disease, genetic or chromosomal anomalies, neurological disease, exposure to anesthesia in utero or prior to PICU admission, GA longer than 60 minutes or repeated PICU sedation since original admission.
  • logistical exclusions: language other than English or French for which testing tools are available; geographical distance precluding return for testing appointment.

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • McGill University Health Center

    Montreal, Quebec, H3Y 3A2

Other trials in Canada

About this study

Official title: Feasibility Study to Determine Ability to Recruit and Assess Patients for a Neurodevelopment Follow-up Study in Pediatric Intensive Care

There is a large and growing body of animal evidence demonstrating neuroapoptosis and neurodevelopmental abnormalities after exposure to anesthetic agents. This has prompted an FDA warning concerning use of anesthetics and sedatives in children under 3 years of age. There has been very little investigation of the neurodevelopment effects of prolonged sedation in previously healthy infants in Paediatric Intensive Care. This feasibility study will recruit previously healthy infants who required respiratory support with or without sedation at up to 1 year of age and assess neurodevelopmental outcomes at 6 years of age.

Read the detailed description

The majority of human cohort investigations of neurotoxicity have studied general anesthesia for surgery. However, many animal studies have involved exposure to agents for significantly longer than the average duration of a general anesthetic in infants, some even for 24 hours (8).This is closer in exposure characteristics to prolonged sedation in PICU: days as compared to a few hours. However, although sedation in the Pediatric Intensive Care Unit (PICU) may continue for several days, there are no studies of its effects on subsequent neurodevelopment in previously healthy young infants. The only intensive care studies thus far have examined high risk subgroups, including the EPIPAGE study (20) in premature newborns and studies of infants after congenital heart surgery. The latter studies have shown a small but significant association between cumulative benzodiazepine dose and Visual-Motor integration at 4 years of age (21), and an association between higher exposure to volatile anesthetic agents and lower cognitive scores on the Bailey Scales of Infant Development III at 12 months (22), respectively.

It is essential that Pediatric Intensivists start investigating the effect of our commonly used sedation protocols, which frequently include benzodiazepines, on our patients' neurodevelopment. The standard sedative regimen in use for many years at Montreal Children's PICU is midazolam infusion (benzodiazepine) plus opioid (commonly fentanyl or morphine) infusion. Other agents including ketamine may be added. This is not an easy field of study since we cannot randomize patients to receive sedation or not.

Therefore this programme of research aims to:

  1. Identify a suitable group of PICU patients who were exposed to PICU sedation, along with a comparable group who were not exposed to sedation during their PICU admission who will act as controls; b) Assess the feasibility of recruiting these retrospectively identified patients and performing the requisite neurodevelopmental assessments around 6 years after PICU admission; c) Expand to a multicentre study, if feasibility is confirmed, to allow the recruitment of sufficient numbers of cases to determine if PICU sedation has a significant effect on long-term neurodevelopment; d) Investigate alternative sedation protocols and/or interventions to minimize the adverse effects on development.
  2. The initial aim of this study programme has been achieved by means of a Chart Review completed in March 2017. We hypothesized that previously healthy infants requiring ventilation for an acute respiratory illness would divide into two groups depending on their respiratory management: intubation with sedation versus non-invasive ventilation without sedation, and that these infants, with a unifying pathological diagnosis, could act as cases and controls for an investigation of PICU sedation. In order to optimize the validity of our comparison, patients must be as similar as possible, therefore many exclusion criteria and also matching are required. The chart review has determined that the two described groups are similar in terms of severity of illness scores (Pediatric Risk of Mortality [PRISM] and Pediatric Logistic Organ Dysfunction [PELOD]) therefore making them suitable subjects for a follow-up study (23). This phase of the programme has been presented and discussed at Canadian Critical Care Trials Group (CCCTG) meetings and endorsed by CCCTG.
  3. Having identified an appropriate group of patients, the next phase of the research programme is to perform a feasibility study to determine if our methodology will lead to adequate recruitment to move forward to a large multicentre study. This is the subject of this protocol.

The proposed methodology is similar to that used successfully in the PANDA study (16) where study participants were identified using billing records (hernia surgery at up to 36 months of age). Their records were checked for exclusion criteria based on age, gestational age at birth and general health. Parents were contacted and invited to participate. Further exclusions were based on more detailed medical history from the parents and the existence of a sibling within 3 years of the index child's age who had not had any anesthetic exposure and who was also healthy. Another general anesthesia study with similar methodology is currently analysing data (24). This group from the Mayo Clinic used population-based controls for anesthesia-exposed index cases identified from a previous cohort study (10). Our participant identification will also be retrospective, from medical records to identify sedation-exposed and non-exposed subjects from within the PICU population as described below.

Hypothesis: feasibility study Patients identified from the PICU admission records and Medical Records search can be suc-cessfully recruited and assessed by standard Neurodevelopmental testing 6 years after their admission.

Hypothesis: definitive study We hypothesize that benzodiazepines alone or with opioid infusion during mechanical ventilation of previously healthy infants with respiratory diagnoses would decrease Wechsler Preschool and Primary Scale of Intelligence III (WPPSI III) score at 6 yrs, compared to infants who were treated with non-invasive ventilation without sedation.

Aims for feasibility study

  1. Identify patients from PICU database and from previous Chart Review Database (see below).
  2. Recruit 20 patients each from the sedated/intubated/ventilated and non-sedated/non-invasive ventilation groups (total 40).
  3. Perform pediatric and neurodevelopmental assessments on patients at 5 years 8 months to 7 years 4 months of age using a battery of tests with Wechsler Pediatric and Primary Infant scales of Development (IV) as the primary outcome.

Primary outcome Successful identification and recruitment of patients and performance of testing.

Secondary outcomes Performance of Wechsler Pediatric and Primary Infant scales of Development IV (WPPSI IV) and NEPSY-II™ tests at 5 years 8 months to 7 years 4 months .

Completion of Childhood Memory Score (CMS™) and Child Behaviour Checklist (CBCL)™ questionnaires Pediatric examination: incidence of neurological abnormalities including cerebral palsy, hearing or visual deficits, seizure disorder, Attention Deficit disorder, Autism spectrum disorder.

Being tested
Sedatives
Keywords
sedation, critical care, infant, neurodevelopment
Medical subject headings
Pneumonia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SedativesDrug

    Also called sedation

    sedated group received sedative drugs to tolerated intubation and ventilation

Study groups in NCT03345628
Study groupRoleWhat they receive
sedatedinfants requiring intubation and ventilation who received sedatives for at least 3 days
Receives: Drug: Sedatives
non-sedatedinfants who received respiratory support by non-invasive ventilation and were not sedated

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Wechsler Pre-school and Primary Scale of Intelligence -IV

    The Wechsler Preschool and Primary Scale of Intelligence consist of 14 subtests. They are designated as one of three types: core, supplemental, or optional. The core subtests are required for the computation of the Verbal, Performance, and Full Scale IQ. Quotient and Composite scores have a mean of 100 and a standard deviation of 15. Subtest scaled scores have a mean of 10 and a standard deviation of 3. A score of 90-109 is Average

    Measured: 6 years

Secondary outcomes (3)
  1. NEuroPSYchological Assessment (NEPSY)

    The six functional domains below are made up of 32 subtests and four delayed tasks. These domains are theoretically, not statistically, derived. The subtests were designed to assess cognitive abilities related to disorders that are typically diagnosed in childhood and that are required for success in an academic environment.

    Measured: 6 years

  2. Childhood Memory Scale (CMS™)

    Pearson Clinical 5-8yrs record form. Assesses children's memory abilities. The CMS is administered to identify deficits in learning and memory. There are six core subtests and three supplemental subtests from which you can derive scaled scores (mean=10, SD=3). You may also derive eight Index Scores (mean 100, SD=15) from various combinations (summation) of subtest scaled scores: Visual Memory Immediate, Visual Memory Delayed, Verbal Memory Immediate, Verbal Memory Delayed, Verbal Memory Recognition, Attention/Concentration and Learning. Finally, Visual Memory Immediate, Visual Memory Delayed, Verbal Memory Immediate and Verbal Memory Delayed Indices can be summed to get a General Memory Score (mean 100, SD=15). A scaled score of 8-12 for the substests is average and a standard score of 90-110 forwppsi the indices is average.

    Measured: 6 years

  3. Child Behaviour Checklist (CBCL)™

    widely used checklist assessing behaviours and emotional responses

    Measured: 6 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Nov 2017
  2. Study start1 Feb 2018
  3. Primary completion30 Dec 2021 (estimated)
  4. Study completion30 Dec 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Other
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03345628
Sponsor's protocol ID
PICU FUN 2018-3310
Acronym
PICUFUN
Status last verified
Feb 2020
First submitted
14 Nov 2017
Last updated
21 Feb 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Bronchiolitis Acute and Pneumonia, run by McGill University Health Centre/Research Institute of the McGill University Health Centre at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Wechsler Pre-school and Primary Scale of Intelligence -IV (time frame: 6 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in